Crossmark

Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy

Crossref DOI link: https://doi.org/10.1007/s00345-022-03963-y

Published Online: 2022-02-26

Published Print: 2022-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Narita, Shintaro https://orcid.org/0000-0003-2988-1860
Kimura, Takahiro

Hatakeyama, Shingo

Hata, Kenichi

Yanagisawa, Takafumi

Maita, Shinya

Chiba, Shuji

Sato, Hiromi

Kashima, Soki

Koizumi, Atsushi

Yamamoto, Ryohei

Takayama, Koichiro

Okane, Katsumi

Ishida, Toshiya

Horikawa, Yohei

Kumazawa, Teruaki

Shimoda, Jiro

Suzuki, Takehiro

Ohyama, Chikara

Egawa, Shin

Nomura, Kyoko

Habuchi, Tomonori
License Information

Text and Data Mining valid from 2022-02-26

Version of Record valid from 2022-02-26
More Information

Article History

Received: 17 November 2021

Accepted: 5 February 2022

First Online: 26 February 2022

Declarations

:

: Shintaro Narita received honoraria from Janssen Pharmaceutical K.K. Takahiro Kimura is a paid consultant/advisor of Astellas Pharma Inc., Bayer AG, Janssen Pharmaceutical K.K and Sanofi S.A. Shin Egawa is a paid consultant/advisor of Takeda, Astellas, AstraZeneca, Sanofi, Janssen, and Pfizer. Tomonori Habuchi also received honoraria from Janssen Pharmaceutical K.K., Takeda Pharmaceutical Company Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Ltd., AstraZeneca K.K., Sanofi S.A., and Bayer AG. The other authors have no disclosures.

: All patients gave opt-out consent for inclusion after being informed of the study and provided information on the institution’s website.

: The study involving human participants.

Document is current

Any future updates will be listed below